< Back to previous page

Researcher

Karine Breckpot

  • Research interest:

    Design of innovative immunotherapy strategies. The strategies under development include ex vivo and in vivo engineering of (1) dendritic cells for immune activation and (2) T-cells for cancer cell rejection, and (3) engineering of the tumor microenvironment to facilitate antitumor immune responses. Technologies such as mRNA, lentiviral vectors and single domain antibodies (better known as nanobodies) are employed for these purposes. Strategies under development are extensively tested in preclinical in vitro models using cells of human and mouse origin as well as in mouse cancer models. Successful strategies are translated towards clinical applications in phase I/II trials.

  • Keywords:Medicine
  • Disciplines:Innate immunity, Adaptive immunology, Inflammation, Cancer biology, Applied immunology , Vaccinology, Cancer therapy , Nuclear imaging
  • Users of research expertise:

    Design of innovative immunotherapy strategies. The strategies under development include ex vivo and in vivo engineering of (1) dendritic cells for immune activation and (2) T-cells for cancer cell rejection, and (3) engineering of the tumor microenvironment to facilitate antitumor immune responses. Technologies such as mRNA, lentiviral vectors and single domain antibodies (better known as nanobodies) are employed for these purposes. Strategies under development are extensively tested in preclinical in vitro models using cells of human and mouse origin as well as in mouse cancer models. Successful strategies are translated towards clinical applications in phase I/II trials.